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Drug delivery and controlled release from
biocompatible metal–organic frameworks
using mechanical amorphization†
Claudia Orellana-Tavra,a Ross J. Marshall,b Emma F. Baxter,c
Isabel Aba´nades La´zaro,b Andi Tao,a Anthony K. Cheetham,c Ross S. Forgan*b and
David Fairen-Jimenez*a
We have used a family of Zr-based metal–organic frameworks (MOFs) with different functionalized (bromo,
nitro and amino) and extended linkers for drug delivery. We loaded the materials with the fluorescent
model molecule calcein and the anticancer drug a-cyano-4-hydroxycinnamic acid (a-CHC), and
consequently performed a mechanical amorphization process to attempt to control the delivery of guest
molecules. Our analysis revealed that the loading values of both molecules were higher for the MOFs
containing unfunctionalized linkers. Confocal microscopy showed that all the materials were able to
penetrate into cells, and the therapeutic effect of a-CHC on HeLa cells was enhanced when loaded
(20 wt%) into the MOF with the longest linker. On one hand, calcein release required up to 3 days from the
crystalline form for all the materials. On the other hand, the amorphous counterparts containing the bromo
and nitro functional groups released only a fraction of the total loaded amount, and in the case of the
amino-MOF a slow and progressive release was successfully achieved for 15 days. In the case of the
materials loaded with a-CHC, no difference was observed between the crystalline and amorphous form of
the materials. These results highlight the necessity of a balance between the pore size of the materials and
the size of the guest molecules to accomplish a successful and efficient sustained release using this
mechanical ball-milling process. Additionally, the endocytic pathway used by cells to internalize these
MOFs may lead to diverse final cellular locations and consequently, different therapeutic effects.
Understanding these cellular mechanisms will drive the design of more effective MOFs for drug delivery
applications.
1. Introduction
Traditional drugs in the form of small molecules circulate in
the blood stream at high concentrations in order to reach the
target tissue at the desired final concentration for serving their
therapeutic effect. However, this practice has significant drawbacks,
covering non-selective biodistribution and poor solubility,
which often results in damage of healthy tissues1 and cardio-
toxicity effects,2 strongly limiting their therapeutic potential.
Several efforts in the drug delivery field have been pursued to
overcome these side effects. By using a drug delivery system
(DDS) it is possible to achieve a controlled release, to improve
drug solubility issues, to confer protection from degradation
and to accomplish a targeted delivery.3–5
DDSs can traditionally be divided into two groups: (i) organic,
such as polymers, micelles, liposomes and protein nanoparticles;
and (ii) inorganic, such as zeolites and mesoporous silica nano-
particles.6 On one hand, the main advantage of the organic
systems are their biocompatibility, whereas their principal draw-
back is their low loading capacities (typically up to 0.25 wt%).7 On
the other hand, inorganic carriers possess well-defined porosity,
resulting in high loadings (up to 40 wt%) and controlled release.
However, their high stabilities make them difficult to degrade
and subsequently remove after drug release.8 Metal–organic
frameworks (MOFs) have appeared as promising DDSs due to
their particular characteristics, such as high pore volumes, large
surface areas, and tuneable pore size and surface chemistry.9,10
During the past decade several therapeutic compounds have
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been loaded in these materials for their use in different
biological applications. Among others, nitric oxide has been
loaded in MOFs for its use in antibacterial, antithrombotic and
wound-healing applications;11 the anticancer cisplatin molecule
and siRNA have been incorporated together in MOFs to enhance
the therapeutic effect;12 numerous anticancer and antiviral agents
have been loaded and released using MOFs and also by applying a
heparin, cyclodextrin or chitosan coatings to Fe-based MOF it has
been possible to improve their biological properties.13–16 Recently,
an in vivo study of these MOF nanoparticles loaded with the
anticancer drug busulfan showed improved pharmacokinetic (PK)
properties compared with commercial solutions.17
Many times, the moderately low chemical and aqueous
stability of MOFs has limited their scope for industrial applica-
tions such as CO2 removal in post-combustion processes.
18
This drawback of MOFs is considered an advantage for drug
delivery applications, as the MOF particles can be biodegraded
and eliminated from the body after the drug is released.
Nevertheless, there are still important limitations for their
use due to the very fast kinetic delivery of up to 3 days from
several drug–MOF complexes.13 In order to address that problem,
we recently performed a mechanical amorphization process to
extend the release time of the fluorescent molecule (calcein) from
2 to more than 30 days in the Zr-based MOF UiO-66 (UiO standing
for University of Oslo).19,20 This amorphous solid was obtained
using a ball-milling process in order to collapse the porosity
around the adsorbed guest molecules, generating a highly
disordered material while conserving the basic metal-linker
connectivity of the original crystalline material, but lacking
long range order.21–24
Here, we have extended our previous study on controlled
release to a family of Zr-based MOFs (Fig. 1a) to analyse the
potential of the technology. We also used confocal microscopy
to confirm the successful incorporation of MOFs into the cells.
We analysed the loading and release of calcein and the anti-
cancer drug a-cyano-4-hydroxycinnamic acid (a-CHC) (Fig. 1b)
in the family of Zr-based MOFs. We used calcein as a model
drug due to its structural similarities to doxorubicin, a well-known
anti-cancer drug. Calcein is also a hydrophilic molecule, which
means it cannot cross the cell membrane, and therefore it needs a
DDS for its efficient intracellular transport. In addition, it is
fluorescent and can be easily detected by confocal microscopy.
Due to its self-quenching characteristics, high local concentrations
of calcein (e.g. when it is adsorbed in aMOF before being released)
cannot be detected until it is released from the material. a-CHC is
a hydrophobic molecule derived from cinnamic acid and it has
shown the ability to inhibit the protein monocarboxylate trans-
porter 1 (MCT1).25,26 This protein is a potential target for cancer
therapy as it has been reported to be upregulated in colorectal and
other types of cancer.27–29
2. Experimental section
Materials
Zirconium tetrachloride (ZrCl4, 99.5%), terephthalic acid (BDC,
98%) and naphthalene-2,6-dicarboxylic acid were bought from
Alfa Aesar (UK). Benzoic acid (99.5%), HCl (37%), dimethyl-
formamide (DMF, 99.8%), L-proline, 2-aminoterephthalic acid,
methanol (99.9%), acetone (99.9%), calcein disodium salt and
a-cyano-4-hydroxycinnamic acid (a-CHC) were obtained from
Sigma-Aldrich (UK). 2-Bromoterephthalic acid and 2-nitrotere-
phthalic acid were obtained from Acros Organics. Azobenzene-
4,40-dicarboxylic acid and 4,40-stilbenedicarboxylic acid were
bought from TCI UK. 4,40-Biphenyldicarboxylic acid was obtained
from Fluorochem.
HeLa cells were obtained from the ATCC. Dulbecco’s modified
Eagle’s medium (DMEM), foetal bovine serum (FBS), L-glutamine,
penicillin, and streptomycin were purchased from Invitrogen
(UK). Phosphate-Buffered Saline (PBS) and trypsin–EDTA, were
purchased from Life Technologiest (UK). The CellTiter 96s
Aqueous One Solution Cell Proliferation Assay (MTS) was
obtained from Promega (UK). All chemicals and biochemicals
used were of analytical grade.
Instruments
All PXRD data were collected in Bragg–Brentano geometry on
a D8 Bruker diffractometer equipped with a primary Ge mono-
chromator for Cu Ka1 and a Sol-X solid state detector. Collection
conditions were: 2–501 in 2y, 0.021 step size, 15 seconds per step,
divergence slits 0.2 mm, receiving slit 0.2 mm. Samples for
scanning electron microscopy (SEM) were scattered onto spectro-
scopically pure carbon tabs (TAAB Ltd UK) and mounted on
aluminium stubs. They were coated with 15 nm of gold in a
Quorum Emitech K575X sputter coater to make them electrically
conductive. They were imaged in an FEI XL30 FEGSEM, operated
at 5 keV, using an Everhart Thornley secondary electron detector.
Colloidal analysis was determined by dynamic light scattering
(DLS) with a Brookhaven Zeta Plus potential analyser (detection
angle of 901 and a 35 mW laser). The measurements were
performed in phosphate-buffered saline (PBS) and growth
media at room temperature. Thermogravimetric analysis (TGA)
was performed using a TA Instruments Q-500 series thermal
gravimetric analyzer, with the sample (0.7–2 mg) held on a
Fig. 1 (a) Chemical structure of the organic linkers used to synthesize the
different Zr-based MOFs (left) and packing structure of Zr–L6 (right);
(b) chemical structure of guest molecules, calcein (left) and a-CHC (right).
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platinum pan under a continuous flow of dry N2 gas. TGA
curves were obtained using a heating rate of 5 1C min1 up to
600 1C. Fourier transform infrared spectroscopy (FTIR) spectra
were recorded in the range 4000–500 cm1 (Perkin Elmer,
Spectrum Two). N2 adsorption isotherms were carried out at
77 K on a Quantachrome Autosorb iQ gas sorption analyser.
Samples were degassed under vacuum at 120 1C for 20 h using
the internal turbo pump.
Synthesis and characterization
Zr–L2 to Zr–L4 were synthesised by adding the required linker
(2.70 mmol, 1 eq.) and ZrCl4 (0.629 g, 2.70 mmol, 1 eq.) to
250 mL reagent bottles. DMF (60 mL) and hydrochloric acid
(0.24 mL) were added and the mixture was sonicated for
10 minutes before being placed in the oven at 120 1C for
24 h. After this time the bottles were removed and allowed to
cool to room temperature. The product was collected by cen-
trifugation, washed with DMF (30 mL) and acetone (2 30 mL).
The samples were placed in a vacuum desiccator to dry.
Zr–L5 to Zr–L8 were synthesised by adding L-proline (1.554 g,
13.50 mmol, 5 eq.), the required linker (2.70 mmol, 1 eq.) and
ZrCl4 (0.629 g, 2.70 mmol, 1 eq.) to 250 mL reagent bottles. DMF
(60 mL) and hydrochloric acid (0.24 mL) were added and the
mixture was sonicated for 10 minutes before being placed in the
oven at 120 1C for 24 h. After this time the bottles were removed and
allowed to cool to room temperature. The product was collected by
centrifugation, washed with DMF (30 mL) and acetone (2 30 mL).
The samples were placed in a vacuum desiccator to dry.
Zr–L1 to Zr–L4 nanoparticles were obtained following the
protocol from Zhu et al.22 with minor modifications. ZrCl4
(0.466g, 2.00 mmol), the required linker (1.93 mmol), (Zr–L1:
terephthalic acid (BDC); Zr–L2: 2-bromoterephthalic acid (Br-BDC);
Zr–L3: 2-nitroterephthalic acid (NO2-BDC); and Zr–L4: 2-aminotere-
phthalic acid (NH2-BDC)), benzoic acid (2.44 g, 20.00 mmol) and
0.33 mL of HCl 37% were dissolved in 36 mL of DMF. The mixture
was placed in a 50mL autoclave and heated at 120 1C for 48 h. After
cooling down to room temperature, the powder corresponding to
each MOF was harvested by centrifugation at 5500 rpm for 20 min
and washed with DMF at room temperature. The particles were
then dispersed and washed with DMF in order to remove the
unreacted linker. The same procedure was repeated with acetone
in order to remove the DMF solvent from the sample. Finally, the
solids were dried at 37 1C in a vacuum oven overnight.
Zr–L5 and Zr–L6 nanoparticles were obtained via solvothermal
reaction conditions modifying a reported protocol.30 Zirconyl
chloride octahydrate (213 mg, 0.66 mmol) was dissolved in
25 mL of DMF. Separately, the required linker (Zr–L5:
naphthalene-2,6-dicarboxylic acid, NDC; Zr–L6: 4,40-biphenyl-
dicarboxylic acid, BPDC) (352 mg, 1.63 mmol) was dissolved in
15 mL of DMF. Both reagent solutions were mixed together in a
100 mL jar, then acetic acid (2.6 mL) was added to the reaction
mixture, which was stirred and placed in the oven at 120 1C for
24 h. On cooling, the nanoparticles were isolated by centrifugation
(4500 rpm, 20 min), and purified by dispersion–centrifugation
cycles with DMF (2) andmethanol (3). The solids were dried in
the high vacuum desiccator for 24 h.
Activation
The powder MOF samples were added to 50 mL PYREX reagent
bottles. THF (30 mL) was added and the jars were placed in the
oven at 50 1C. The THF was exchanged for fresh THF over 4
consecutive days. The THF was then removed and the MOFs
were dried in a vacuum desiccator.
Simulations
Grand canonical Monte Carlo (GCMC) simulations were employed
to obtain the N2 adsorption isotherms at 77 K for the series of
Zr-based MOFs. We used an atomistic model for all MOF
structures, in which the framework atoms were kept fixed at
their crystallographic positions. N2–N2 and N2–MOF interactions
were calculated with a Lennard-Jones (LJ) + Coulomb potential.
The LJ potential parameters for the framework atoms were
adopted from Dreiding31 force field except for Zr atoms, which
were taken from UFF.32 N2 molecules were described by the
TraPPE model.33 The simulation box consisted of 8 unit cells
(2  2  2) for Zr–L1 to Zr–L4, and 1 unit cell (1  1  1) for the
rest of the MOFs. Lorentz–Berthelot mixing rules were used for
all cross terms. A cut-off radius of 12.8 Å was applied to the
Lennard-Jones (LJ) interactions, while the long-range electro-
static interactions were handled by the Ewald summation
technique. Periodic boundary conditions were applied in all
three dimensions. A Peng–Robinson equation of state was used
to convert the pressure to the corresponding fugacity used in
the GCMC simulations.34 For each state point, GCMC simula-
tions consisted of 2  104 Monte Carlo cycles to guarantee
equilibration, followed by another 2  104 production cycles to
calculate the ensemble averages. A cycle consists of ‘‘n’’ Monte
Carlo steps; where ‘‘n’’ was equal to the number of molecules
(which fluctuates during a GCMC simulation). All simulations
included random insertion, deletion, translation and rotation
moves of molecules with equal probabilities. GCMC simulations
report the absolute adsorption data which are then used to
compute the excess adsorption data for comparison with experi-
mental data using the relation from eqn (1):
Ntotal = Nexcess + rgas  Vp (1)
where rgas is the bulk density of the gas at simulation conditions,
and Vp is the pore volume calculated by the helium Widom
insertion method.35,36 In this numerical Monte Carlo integration
technique, helium was modelled as a LJ fluid (s = 2.58 Å, e/kB =
10.22 K) and the force fields used for the framework atoms were
the same as those used in the GCMC simulations.
BET analysis
BET method was used to perform the surface area analysis of
the MOFs.37 The monolayer capacity nm was calculated from the
adsorption isotherm using the BET eqn (2):
P
P0
v 1 P
P0
  ¼ 1
vmC
þ C  1
vmC
P
P0
 
(2)
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where n is the adsorbed amount at a specific relative pressure
P/P0, nm is the monolayer capacity and C is a constant related
with the attractive N2–N2 and N2–MOF interactions. Rouquerol’s
consistency criteria were applied to the N2 77 K isotherms in order
to obtain the BET area values.38
Stability
Linker release experiments were performed in an incubator at
37 1C with orbital agitation and using phosphate buffered
saline (PBS, 10 mM) at pH 7.4 in order to simulate physiological
conditions or water. 5 mg of empty MOF was placed into a
dialysis bag (Medicell International, MWCO molecular weight
cut-off 3500 Da) with a total volume of 10 mL of PBS or water.
At different times, 1 mL of liquid was taken and replaced with
1 mL of fresh PBS or water. The amount of linker released was
measured using a UV-vis spectrophotometer at 240, 240, 225,
229, 284, 281 and 330 nm for Zr–L1 to Zr–L8, respectively. The
corrected concentration of linker release is given by the eqn (3):
ct ¼ ct0 þ v
V
Xt1
0
ct
0
(3)
where ct is the corrected linker concentration at time t, ct0 is the
apparent linker concentration, v is the sample taken and V is
the total volume of the solution. Every experiment was performed
in triplicate.
Drug loading experiments
Calcein adsorption was performed by soaking 100 mg of acti-
vated MOF in 25 mL of a methanolic calcein solution (5 mgmL1)
at 37 1C under orbital agitation for 6 days. The a-CHC loading was
achieved by soaking 250 mg of solids in 25 mL of a methanolic
a-CHC solution (10mgmL1) at room temperature under stirring.
In both cases the loaded MOFs were collected by centrifugation at
5500 rpm for 20 minutes, washed twice with methanol, centri-
fuged again for 10 minutes and dried overnight at 80 1C to remove
the solvent. The amount of calcein adsorbed was quantified by
TGA and, in the case of a-CHC, a UV-vis spectrophotometer at
337 nm measured the amount of drug present in the supernatant
after the first centrifugation step. The loaded amount is given by
the eqn (4):
Loading wt%ð Þ
¼ a-CHCadded ðmgÞ  a-CHCfinal ðmgÞð Þ
a-CHCadded ðmgÞ  a-CHCfinal ðmgÞð Þ þMOF ðmgÞ
(4)
Amorphization
0.1 g of calcein or a-CHC loaded MOF was placed in a stainless
steel jar along with an 8 mm stainless steel ball. The jar was
then oscillated at 20 Hz for 30 minutes using a Retsch MM200
mill resulting in amorphous loaded MOF.
Delivery
Calcein and a-CHC release experiments were performed in an
incubator at 37 1C with orbital agitation and using phosphate
buffered saline (PBS, 10 mM) at pH 7.4 in order to simulate
physiological conditions. 5 mg of drug-loaded particles were
placed into a dialysis bag (Medicell International, MWCOmole-
cular weight cut-off 3500 Da) with a total volume of 10 mL of
PBS. At different times, 1 mL of PBS was taken and replaced with
1 mL of fresh PBS. The amount of drug released was measured
by using a UV-vis spectrophotometer at 498 and 337 nm for
calcein and a-CHC, respectively. The corrected concentration of
drug released is given by the eqn (3). Every experiment was
performed in triplicate.
Cell culture
HeLa cells were maintained at 37 1C with 5% CO2 in high rich
glucose (4500 mg L1) Dulbecco’s modified Eagle’s Medium
(DMEM) supplemented with 10% (v/v) Fetal Bovine Serum (FBS),
2 mM L-glutamine, 100 units mL1 penicillin and 100 mg mL1
streptomycin. The cells were passaged three times a week (at
75–80% of confluence) at a density of 2.8  104 cell per cm2.
Cytotoxicity assay
The cytotoxicity activity of a-CHC, as well as empty and loaded
Zr-based MOFs, was investigated using the 3-(4,5-dimethyl-
thiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-
tetrazolium (MTS) (Promega, UK) reduction assay. The day before
the experiment, the cells were seeded into a 96 well plate at a
density of 5  103 cells per well. Prior to the treatments, the cells
were washed twice with PBS. The different MOF and a-CHC
concentrations were dispersed in cell culture media. Then they
were added to the cells and incubated for 24 h at 37 1C with 5%
CO2. To measure the toxicity, the cells were washed extensively to
remove the solids, the media was replace with 100 mL of fresh
culture media containing 20 mL of MTS/phenazine methosulfate
(in a proportion 20 : 1) solution and the plate was incubated for
1 h and 15 min at 37 1C with 5% CO2. The plates were then read
by UV-vis spectroscopy at 490 nm.
LDH assay
Cell membrane integrity of HeLa cells after treatment with
empty MOFs was measured using Pierce LDH Cytotoxicity Assay
Kit (Thermo Scientific). The day before the experiment, the cells
were seeded in to a 96 well plate at a density of 5  103 cells per
well. Prior to the treatments, the cells were washed twice with
PBS. The different MOFs concentrations were dispersed in cell
culture media, then added to the cells (110 mL) and incubated
for 24 h at 37 1C with 5% CO2. The next day two controls were
prepared: spontaneous LDH activity and maximum LDH activity
controls. 10 mL of distilled water and 10 mL of Lysis buffer (10),
respectively, was added to a triplicate set of wells containing cells
in 100 mL of complete growthmedia. The plate was incubated for
45 min at 37 1C with 5% of CO2. Consequently, 50 mL of each
sample was transferred to a new 96-well plate. 50 mL of the
reaction mixture (supplied by the provider) was added and the
plate was incubated at room temperature for 30 min protected
from light. To stop the reaction, 50 mL of the stop solution
(supplied by the provider) was added and the absorbance was
measured at 490 and 680 nm. To determine the LDH activity, the
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absorbance at 680 nm (background) was subtracted from the
490 nm absorbance. Finally, the toxicity was calculated using
eqn (5):
Confocal microscopy
HeLa cells were seeded in a NUNCTM imaging four-well plate at
a density of 1.11  105 cell per mL and incubated for 24 h at
37 1C with 5% CO2 in DMEM supplemented with 10% (v/v) Fetal
Bovine Serum (FBS), 2 mM L-glutamine, 100 units mL1 peni-
cillin and 100 mg mL1 streptomycin. The cells were then
washed twice with PBS and incubated together with 0.5 mg mL1
of each Zr-based MOF for 24 h. The MOFs were well dispersed
in culture media before being added to the well plates contain-
ing the cells. Untreated cell and free calcein were included as
controls (0.075 mg mL1). After the incubation time, cells were
washed several times to remove all the non-internalized parti-
cles. Cells were then incubated for 15 min with 5 mg mL1 of
Hoechst 33342 (H33342) and 1X of CellMaskt Orange to stain
the nucleus and cell membrane, respectively. Cells were then
washed extensively to remove the dyes and fresh media without
phenol red was added to each sample. Finally, the four-well
plate was placed on a Leica TCS SP5 confocal microscope to be
imaged. The microscope was equipped with 405 diode, argon
and HeNe lasers. Leica LAS AF software was used to analyse
the images.
3. Results and discussion
Zirconium-based MOFs have demonstrated reasonable aqueous
stability.20,39 Zirconium also exhibits low toxicity; the lethal dose
(LD50) of zirconyl acetate is B4.1 mg mL
1 in rats while the
human body contains B300 mg of Zr and the amount daily
ingested is B3.5 mg per day.40 Additionally, UiO-66
([Zr6O4(OH)4(BDC)6], BDC = 1,4-benzenedicarboxylate) has an
IC50 value on HeLa cells of 1.503  0.154 mg mL1 after 24 hours
of exposure.19 This well-known MOF possess a cubic structure
based on Zr-oxo clusters and BDC linkers, resulting in a large
porosity (SBET = 1200 m
2 g1, Vp = 0.5 cm
3 g1) and two main
cavities (ca. 11 and 8 Å diameter).41 The replacement of the original
BDC linker by linkers with functional groups such as bromo,
amino and nitro allows the modification of the adsorption pro-
perties of MOFs,42,43 whereas the use of longer organic linkers
generates MOFs with larger pore volumes.9,44 Fig. 1 highlights the
eight different linkers used to construct the isoreticular Zr-based
family of MOFs used during this study. We named these linkers as
L1 to L8 where L1 is 1,4-benzenedicarboxylate (BDC), used for
UiO-66, L2–L4 are functionalised forms of BDC and L5–L8 are
extended linkers. We refer to the synthesized MOFs as Zr–Lx,
where x denotes the identification number of the linker.
3.1. Physical characterisation
We used powder X-ray diffraction (PXRD) to confirm the crystalline
structure of the MOFs and compared them with the patterns
predicted from single crystal X-ray structures.45,46 Fig. S1 (ESI†)
shows the patterns of the synthesized MOFs, confirming the
crystalline nature of each material. Scanning electron microscopy
(SEM) images indicate that some of the MOFs grew in the form
of interconnected crystals and that Zr–L1 was in the range of
nanometers whereas Zr–L2 to –L8 were in the micron range
(Fig. S2, ESI†).
We analysed the porosity of the Zr-based MOFs by measuring
their N2 adsorption isotherms, and compared them to the results
obtained using grand canonical Monte Carlo (GCMC) simula-
tions. Fig. 2 shows the comparison of the experimental and
simulated N2 adsorption isotherms at 77 K for Zr–L1 and Zr–L7
while Fig. S3 (ESI†) presents the linear and semi-log isotherms
for the all the MOFs. Based on the IUPAC classification, all the
simulated curves represent Type I isotherms, typical of micro-
porous materials, whereas the experimental ones are Type II,
showing the presence of multilayer adsorption and occasionally
saturation at high relative pressures (e.g. Zr–L1, Zr–L2, Zr–L4)
due to the presence of interstitial spaces between particles and/
or mesoporosity caused by the existence of crystalline defects,
such as linker vacancies.47 The simulation results, with the
exception of Zr–L4 and Zr–L6, overestimated experimental
results at low partial pressures (below 0.1 P/P0). These discre-
pancies are attributed to an overestimation of the interactions
between N2 and the MOFs.
48,49 This effect is more appreciable in
the case of the MOFs with smaller pore sizes (Zr–L1 to Zr–L4).
Fig. S4 (ESI†) shows the comparison of pore size distributions
(PSDs) calculated using QSDFT (slit pore, N2 at 77 K on carbon
kernel) on the experimental N2 adsorption isotherms, with those
obtained using a pure geometrical analysis based on crystallo-
graphic data (i.e. simulated). Experimental and simulated PSDs
are in a reasonable good agreement. In general the simulated
results underestimate the pore size for MOFs containing func-
tional groups although they are in excellent agreement for MOFs
containing elongated linkers. This probably reflects the fact that
simulations consider a perfect framework, however function-
alised MOFs present noticeable defects, as seen in their experi-
mental adsorption isotherms.
Fig. 2 N2 adsorption isotherms measured at 77 K for (a) Zr–L1 and
(b) Zr–L7. Experimental (black close dots) and GCMC simulated (red open
dots) data.
LDH release ¼ Compound-treated LDH activity Spontaneous LDH activity
Maximum LDH activity Spontaneous LDH activity  100 (5)
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Table 1 shows the comparison of experimental and simulated
BET areas. As expected, differences in the length of the linkers
affect the BET areas, with experimental values ranging from 607 to
3024 m2 g1 for Zr–L2 and Zr–L8, respectively. With the exception
of Zr–L3 and Zr–L4, the experimental BET areas are lower than the
simulated results, reaching in some cases differences of 20%
(Zr–L7). This indicates experimental issues with the crystallinity
of the MOFs and/or their activation. Overall, the porosity of the
experimental samples seems to be described reasonably correctly
by perfect crystalline models.
3.2. Stability
In order to study the aqueous stability of the MOFs, we measured
the release of the linker from the empty MOFs in phosphate-
buffered saline (PBS) and water at different times. Fig. 3a and
Fig. S5 (ESI†) show the degradation patterns for Zr–L3 and all
the Zr-based family, respectively, confirming that all the MOFs
were more stable in water than in PBS. As seen previously for UiO-
66, UiO-66-Br and UiO-66-NH2, PBS accelerates the breakdown of
the MOFs.50 Phosphate groups (PO4
3) present in the PBS buffer
attack the metal clusters of the MOF, substituting the carboxylic
linkers, and finally disrupting the crystalline MOF structure.
The crystallinity of the MOFs was evaluated after 2 days of PBS
exposure by determining their PXRD pattern (Fig. 3b and Fig. S6,
ESI†). The results showed that after the incubation time all of the
MOFs were completely amorphous or at least part of their crystal-
linity was lost. In order to further study this phenomenon, the
different MOFs were incubated for 2 and 3 days in PBS and then
characterized using Fourier Transform Infrared Spectroscopy
(FTIR) (Fig. 3c and Fig. S7, ESI†). In the original MOF, the intense
signals between 1590 and 1400 cm1 are attributed to carboxylate
linkers; the triplet around 725 and 550 cm1 is assigned to the
Zr–O vibrational modes.51 In the PBS treated MOFs, FTIR showed
the presence of phosphates groups around 1000 cm1. An
exchange of the linkers for phosphates groups has occurred, i.e.
there is coordination between Zr and PO4
3, as the intensity of the
peaks from the phosphate groups increased over time while the
carboxylate group decreased. As PO4
3 is an electrolyte present in
the body, the MOFs are therefore expected to biodegrade with no
accumulation in cells.
3.3. Cytotoxicity
Toxicity evaluation of the carriers is a key step in the development
of an efficient DDS as it is crucial to reduce any undesired
detrimental effect of the systems on cells. We also measured the
effect of the organic linkers and zirconium salt, i.e. the individual
building blocks after the MOF degradation. The effect of the MOFs
on cells was determined by measuring the metabolic activity using
the MTS reduction assay. Fig. 4 shows the viability values of Zr–L3
and L3 linker; Fig. S8a (ESI†) shows the viability values of the
MOFs; all the MOFs were biocompatible except Zr–L8 where the
cell viabilitydecreased to ca.60%at0.1mgmL1MOFconcentration.
For this reason Zr–L8 was discarded from further experiments.
Fig. S8b shows the viability values for ZrCl4 and each linker; all the
compounds were harmless to cells with the exception of L7. In this
case, the viability decreased dramatically to ca. 40% when the cells
where incubated with only 0.1 mg mL1 of L7.
Table 1 Comparison of BET surface area from experimental and simu-
lated results
MOF
Simulated BET
area (m2 g1)
Experimental BET
area (m2 g1)
Zr–L1 1288 1156
Zr–L2 732 607
Zr–L3 765 794
Zr–L4 916 1031
Zr–L5 1492 1295
Zr–L6 3010 2483
Zr–L7 3634 2907
Zr–L8 3494 3024
Fig. 3 Stability analysis for Zr–L3. (a) Degradation pattern in PBS (black
closed dots) and H2O (red open dots). (b) PXRD patterns of calculated
Zr–L3 (black), synthesized (blue) and samples incubated for 2 days in PBS
(red). (c) FTIR analysis after PBS exposure for 0 days (black), 2 days (red) and
3 days (blue).
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To complement the measurement of metabolic cellular activity
obtained through the MTS assay, we evaluated the cell membrane
integrity. For this purpose we quantified the amount of lactate
dehydrogenase (LDH) enzyme released to the media from
damaged cells.52 Fig. 4 and Fig. S9a, b (ESI†) show the normalised
levels of LDH released, for Zr–L3 and L3, all the MOFs, and all
the building blocks, respectively, over the maximum amount of
released LDH from lysed cells. LDH is a cytoplasmic enzyme
present in several cell types and its release from normal cells is
minimal – high levels of LDH in the extracellular media is
therefore an indicator of cell membrane damage. The LDH release
values obtained were extremely low compared with the control
(i.e. lysed cells), and therefore it is possible to appreciate that
neither the MOFs nor their components separately affected the
permeability of the cells. Based on the two viability assays, Zr–L1
to Zr–L6 were selected for the drug adsorption experiments, as
those are the most suitable MOFs for drug delivery applications in
terms of biocompatibility.
3.4. Drug adsorption experiments
Calcein was loaded into the MOFs by soaking the solids in a
methanolic calcein solution, generating the cal@Zr–Lx MOFs.
We did not incorporate Zr–L1 into this analysis as we have
previously studied this calcein loaded MOF in its crystalline
and amorphous form.19 In parallel, we loaded the MOFs with
a-CHC using a similar procedure, producing the a-CHC@Zr–Lx
solids. In both cases the MOFs maintained the original crystal-
line structure after loading (Fig. S1, ESI†). Table 2 shows the
different loading values for the two molecules used. The low
loading values of calcein for Zr–L2 to Zr–L4 compared with
Zr–L1 may be attributed to an impediment of the large calcein
molecules accessing the cavities of the MOFs due to the
presence of the functional groups in the pores, as reflected in
their lower experimental and predicted BET surface areas. In
the case of Zr–L5 and Zr–L6 MOFs with longer linkers, the
amount adsorbed increased, reaching B15 wt% in the case of
L6. Thus, a MOF with longer linker would be ideal to load larger
molecules such as calcein. A similar effect can be observed for
a-CHC where the loading in Zr–L1 is ca. 31 wt%, whereas when
the MOFs are functionalised (Zr–L2 to Zr–L4) the loading
decreased down to ca. 3–7 wt%. Although the length of
a-CHC is approximately 10.6 Å, from the OH- to the COOH-
group, and the width of the aromatic ring is 5.9 Å, which is
comparable with the pore gate of Zr–L1. The presence of crystal
defects such as missing linkers reported in Zr–L147,53 would
allow the diffusion of the drug inside the MOF porosity. For the
MOFs with longer linkers, the loading increased up to 20.3 wt%
for Zr–L6. These loadings are in the same range as values
reported for zeolites (i.e. 7–14 wt%).25
In order to control the drug release, we performed the
amorphization of the loaded MOFs by using a ball-milling
process, producing the cal@amZr–L1–6 and a-CHC@amZr–L1–
6 MOFs. PXRD patterns of the amorphous MOFs are presented
in Fig. S1 (ESI†); the disappearance of all the representative
Bragg peaks confirms the success of ball-milling. Previous
studies on mechanical and pressure-induced amorphization
have demonstrated that the BET surface area of the amorphous
MOFs decreased as a function of the amorphization time and
pressure applied, respectively.23,54 Fig. 5 shows the release
profiles of calcein and a-CHC from amorphous and crystalline
Zr–L4 and Zr–L5 respectively, whereas Fig. S11 (ESI†) shows the
release profiles of both molecules for all the MOFs.
For calcein, the molecules were released from all the crystal-
line MOFs in approximately 2–3 days presenting a burst effect
during the first hours of release, whereas the profiles from the
amorphous MOFs were different in each case. For amZr–L2 and
amZr–L3, the calcein molecules were trapped in the framework,
and only a fraction of the total loaded amount, 63 and 68 wt%,
respectively, was released. In the case of amZr–L4, a slower and
Fig. 4 LDH assay for Zr–L3 (black bars) and L3 linker (white bars). The
error bars represent the standard combined error of three independent
samples.
Table 2 Loading of calcein and a-CHC on the different Zr-MOFs
MOF Calcein (wt%) a-CHC (wt%)
Zr–L1 4.919 31.0
Zr–L2 1.0 3.1
Zr–L3 1.0 5.0
Zr–L4 1.2 7.2
Zr–L5 2.1 14.8
Zr–L6 15.2 20.3
Fig. 5 Release profile of (a) calcein from Zr–L4 and (b) a-CHC from
Zr–L5. The crystalline MOF is presented in black closed dots and amor-
phous in red opened dots. Black solid and red dotted lines represent the
kinetic of delivery fitting using non-linear regression on crystalline and
amorphous MOFs, respectively.
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progressive released was observed during 15 days. Finally, for
Zr–L5 and Zr–L6 there was no significant difference between
the crystalline and amorphous patterns. In the latter case of
the MOFs with longer linkers, it is possible that after the ball-
milling the porosity was not completely blocked, allowing the
diffusion of guest molecules. Also, since the stability of loaded
MOFs against the amorphization process increases,55 Zr–L6,
with a higher drug loading, might be affected differently by the
amorphization process. As the particle size of the MOFs was not
suitable for cellular uptake, it was not possible to perform
confocal microscopy to visualise the slower in vitro release,
particularly for Zr–L4 and amZr–L4.
Fitting of release patterns showed a simple hyperbolic curve
for Zr–L3 to L6, amZr–L3 and amZr–L6, whereas Zr–L2, amZr–L2,
amZr–L4 and amZr–L5 showed a two stage profile. Full details of
the equations can be found in the ESI† (Tables S2 and S3). During
the first stage of the delivery, the release of calcein occurs
probably through desorption and diffusion from the porosity of
the MOFs. The second release phase may be related with the
partial dissolution of the amMOF to liberate the remnants of the
encapsulated calcein. Only in the case of amZr–L4 does this two
stage profile allow for a slower release of calcein.
a-CHC was delivered from all the crystalline MOFs in ca.
1 day presenting a burst effect during the first hours of release,
except Zr–L3, which reached 94 wt% release after 3 days. No
significant difference between the crystalline and amorphous
patterns was observed. Here again, either the obstruction of the
pore gates was not enough to avoid the diffusion of the small
a-CHC molecules, or the loaded molecules increased the sta-
bility of the MOFs against the amorphization process.56 Fitting
release patterns for these MOFs revealed a two-stage release for
the crystalline and amorphous solids. This possibly is related
with a higher interaction of the a-CHC molecules and the
frameworks compared to calcein, where only Zr–L2 presented a
two-stage release before the ball-milling process. The amorphiza-
tion process did not contribute to any significant improvement
in the delivery time. These results stress the importance of the
system chosen for achieving a slow release using this technique.
A balance between the pore size and the size of the guest
molecules is crucial to have a successful sustained release through
this mechanical ball-milling process.
3.5. Cellular uptake and in vitro experiments
In order to study in vitro the cellular uptake of the MOFs, we
synthesised the selected MOFs on the nanoscale; for details of
the synthesis procedure refer to the Experimental section.
Fig. S12 (ESI†) shows the SEM images for all the nano-sized
MOFs, confirming the nanoparticulate nature. Since the physico-
chemical characteristics of the particles can be modified in
suspension,57,58 we measured the colloidal stability of the MOFs
to determine their hydrodynamic diameter and to study the
aggregation of particles in PBS and growth media.
Table 3 shows the effective diameter in both media. It shows
that the degree of aggregation was higher when the MOF particles
were suspended in PBS compared to growth media. Since MOFs
exhibit different degrees of hydrophobicity,41 they are prone to
agglomerate in PBS. On the other hand, the adsorption of
different kind of proteins from the growth media in the external
surface of the MOF particles, forming a ‘‘protein corona’’,59
might be the reason of their improved water stabilities. We also
studied how the particle size of the MOFs affected the viability
of cells by using an MTS cytotoxicity assay. Fig. S13 (ESI†) shows
the viability values of HeLa cells after incubation with each
nano-sized MOF in a concentration varying from 0 to 1 mg mL1.
None of the nano-sized MOFs presented any significant negative
effect on cells.
Fig. 6 shows the confocal microscopy images of HeLa cells
incubated for 24 h with free calcein, and for all the nano-sized
cal@MOFs. We used Hoechst 33342 (H33342) and CellMaskt
Orange for staining the nucleus and the plasma membrane of
the cells, respectively. Cells incubated with free calcein stained
weakly in the form of bright vesicles at 24 h of incubation,
suggesting that calcein is encapsulated in endosomes. Although
calcein is considered impermeable to cell membranes, cellular
uptake of impermeable dyes by endocytosis has been reported
previously using Human Mesenchymal Stem Cells (MSCs) and
the dye Lucifer yellow (LYCH).60 We have also observed this
phenomenon previously.19 When cells were incubated together
with the Zr-based MOFs, a strong signal was detected after 24 h,
confirming that the MOF particles were successfully incorpo-
rated by cells. The punctate staining in the confocal images
suggests MOF entrapment within intracellular vesicles. We can
confirm that the MOFs are effectively inside the cells and not
on the external part of the cell membrane because it is possible
to visualize the cellular nucleus (blue), the MOF particles
(green) and only the periphery of the cells in red, confirming
that the image is an internal plane of the cells.
We also measured the therapeutic effect of a-CHC loaded in
the nano-sized Zr-based MOFs by using an MTS assay. Table S4
(ESI†) presents the drug loading values, which are similar
to those obtained for larger particle sizes. Fig. 7 presents
the viability values for cells incubated for 24 h with either
a-CHC@Zr–L1 or a-CHC@Zr–L6 at different concentrations
compared with the empty corresponding MOF amount. Fig. S14
shows the analysis for the other Zr-based MOFs. The amount of
MOF in the loaded samples was maintained at the same concen-
tration as the empty MOFs (0.25, 0.5 and 1 mg mL1) to allow
comparison.
There was no significant difference in the viability for cells
treated with empty and loaded Zr–L1 to Zr–L5 as the levels
remained similar, over 80% for both conditions at equal
Table 3 Colloidal analysis of nano-sized Zr-based MOFs measured in PBS
and growth media
MOF
Effective diameter (nm)
PBS Growth media
Zr–L1 831  157 156  6
Zr–L2 709  13 237  157
Zr–L3 961  16 596  18
Zr–L4 828  84 165  1
Zr–L5 1319  247 86  13
Zr–L6 12742  3319 137  25
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concentration of MOF. In the case of Zr–L6, it presented a
significant difference (Pr 0.05), down to 59  5% viability, when
cells were treated with 1 mg mL1 of loaded MOF. A similar result
was expected for Zr–L1 as its loading value was even higher than
Zr–L6. A plausible explanation may be that cells are using different
mechanisms for internalizing each MOF; different endocytic
pathways may lead to diverse final destinations inside cells and
thus, different therapeutic effects.61 Similar results have been
found previously in other MOF studies, where there was no
significance difference between using either free drug, empty
MOFs or loaded MOFs.51,62,63 Future work studying the uptake
mechanisms of these MOFs is currently in progress in order to
allow a more efficient design of MOFs for this application.
4. Conclusions
We successfully synthesised and characterized a Zr-based family of
MOFs. The MOFs are biocompatible in the concentration range
evaluated and they were also able to penetrate into cells, demon-
strating their potential use as a DDS.We carried out the adsorption
of a fluorescentmolecule (calcein) and a therapeutic agent (a-CHC)
in these solids achieving different degrees of loading depending
on the MOF and the guest molecule. Additionally, we have shown
that by performing a mechanical amorphization it was possible to
entrap calcein molecules in the MOFs and in the case of amZr–L4
achieve a slower release of up to 15 days. Finally, the therapeutic
effect of a-CHC loaded in each Zr-based MOF was evaluated,
resulting in an enhanced effect of the drug when loaded into
Zr–L6. Future work on understanding the cellular internalization
mechanism is needed to complement the design of MOF for drug
delivery application.
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